Aptagen, LLC
            
                
                    
                                                     * The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
                                            
                                            * The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
                                    
                
                                            
            
            
            
            
        
    Human Matrix Metalloprotease 9 (hMMP-9) (F3Bomf) (ID# 7743)
 
                                            
                            
                            Chimeric
                        
                    
                                            
                            
                            Human matrix metalloprotease 9 (hMMP-9)
                        
                    
                                            
                            
                            Protein
                        
                    
                                            
                            
                            20 nM (reported value)
                        
                    
                                            
                            
                            SP buffer: 50 mM Tris HCl, pH 7.4, 50 mM NaCl, 100 mM KCl, 5 mM CaCl2, 1 mM Magnesium Acetate.
                        
                    
                                            
                            
                            23°C
                        
                    
                    
                        
                        
                                                            NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.                         
                    
                                            
                            
                            Labels: Grade I Pilocytic astrocytoma, Grade I Meningioma, Grade II Astrocytoma, Grade II Ependymoma, Grade III Anaplastic astrocytoma, Grade IV Glioblastoma, Grade IV medulloblastoma, Grade IV lymphoma.  Does not label healthy brain tissue.
                        
                    
                                            
                            
                            This aptamer is a truncated and modified version of FB3
                        
                                    
                
                
                    5'-fUpmGpfCpfCpfCpfUpmGpfCpfCpfCpfUpfCpmApfCpfCpfCpmGpfUpfUpmApmGpfCpfCpfUpmGpmApmGpfCpmGpfCpfCpfCpfCpmGpfCpmAp-3'
                
                
                     
                
                                    
                        
                        
                            
                    
                
                
                
            
            
         
                
                        
                        36
                    
                
                                    
                        
                        11563.12
                    
                            
                                    
                        
                        311900
                    
                            
                
                
                Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
S Gomes et al. A 99mTc-MAG3-aptamer for imaging human tumours associated with high level of matrix metalloproteinase-9. Bioconjugate Chem. (2012). Accepted for print. DOI: 10.1021/bc300146c.
Have your aptamer oligo synthesized ORDER



We are always looking for ways to improve. Please tell us what you think.